A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Squamous Cell
  • Gonanes
  • Head and Neck Neoplasms
  • Neoplasm Metastasis
  • Phosphatidylinositol 3-Kinases
  • Taxoids

abstract

  • The addition of PX-866 to docetaxel did not improve PFS, RR, or OS in patients with advanced, refractory HNSCC without molecular pre-selection.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4857706

Digital Object Identifier (DOI)

  • 10.1016/j.oraloncology.2014.12.013

PubMed ID

  • 25593016

Additional Document Info

start page

  • 383

end page

  • 8

volume

  • 51

number

  • 4